The UC space is highly diversified with a number of molecules approved. In October 2023, the FDA approved Omvoh (mirikizumab), an interleukin-23 antagonist developed by Eli Lilly. It is indicated ...

The company’s chatbot can now create elaborate and unusual images. By Cade Metz Reporting from San Francisco Chatbots were originally designed to chat. But they can generate images, too.

Design by MNT; Photography by LumiNola/Getty Images & seb_ra/Getty Images People with inflammatory bowel disease (IBD) have an increased risk of developing Parkinson’s disease, a ...

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48. 3 ...

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn's disease 1,2< ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the first drug in the class available in both intravenous and subcutaneous ...

We recently published a list of 15 Dividend Zombies to Invest in. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other dividend zombies to ...

along with approval for Omvoh for managing moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY), one of the best dividend zombies, has been paying dividends to ...

This article delves into the three approved assets in this class – AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Omvoh (mirikizumab), and J&J’s Tremfya (guselkumab) – and explores how ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This approval is the fourth ...

Data captured from pediatric patients revealed a relationship between high burden of common infection episodes in early life and increased risk for moderate to severe infections in later childhood ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in.In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best ...